Literature DB >> 20543721

Hepatorenal syndrome: diagnosis and effect of terlipressin therapy in 4 pediatric patients.

Nadya Yousef1, Dalila Habes, Oanez Ackermann, Philippe Durand, Olivier Bernard, Emmanuel Jacquemin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20543721     DOI： 10.1097/MPG.0b013e3181d60e73

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  6 in total

1.  Clinically Evident Portal Hypertension: An Operational Research Definition for Future Investigations in the Pediatric Population.

Authors:  Lee M Bass; Benjamin L Shneider; Lisa Henn; Nathan P Goodrich; John C Magee
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-06       Impact factor: 2.839

Review 2.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

Review 3.  Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.

Authors:  Shikha S Sundaram; Cara L Mack; Amy G Feldman; Ronald J Sokol
Journal:  Liver Transpl       Date:  2017-01       Impact factor: 5.799

Review 4.  Acute kidney injury in children with chronic liver disease.

Authors:  Akash Deep; Romit Saxena; Bipin Jose
Journal:  Pediatr Nephrol       Date:  2018-03-01       Impact factor: 3.714

5.  Use of terlipressin in critically ill children with liver disease.

Authors:  Romit Saxena; Aravind Anand; Akash Deep
Journal:  BMC Nephrol       Date:  2020-08-20       Impact factor: 2.388

Review 6.  Hepatorenal syndrome in children: a review.

Authors:  Sarah Tayná de Carvalho; Pollyanna Faria Fradico; Maria Luiza Barreto Cazumbá; Ramon Gustavo Bernardino Campos; Priscila Menezes Ferri Liu; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2020-10-01       Impact factor: 3.714
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.